Abstract 299P
Background
Nasopharyngeal cancer is the most common head and neck cancer in Indonesia with prevalence of 28.4% among all adult head and neck cancer. Radiotherapy and chemotherapy are the main modalities for nasopharyngeal cancer treatment, With proper treatment, patients with nasopharyngeal cancer would have 5-year survival rate of above 80%, even in locally advanced nasopharyngeal cancer. However toxicity associated with nasopharyngeal cancer treatment is quite burdensome for the patients especially toxicity in terms of hematology, mucositis, nausea, and vomiting. Due to the burdening toxicity of chemoradiation treatment for the patients, several chemotherapy schedules were attempted. We aimed to search and elucidate high quality evidence available to date to answer our clinical question, whether triweekly or weekly concurrent chemoradiation is better for nasopharyngeal cancer treatment in terms of survival.
Methods
Literature searching was conducted on 3 databases: PubMed, EBSCOhost, and Scopus using keyword “Nasopharyngeal Cancer”, “Weekly Chemotherapy”, “Triweekly Chemotherapy”, “Overall Survival” and its synonyms using both MeSH and non-MeSH terms. Critical Appraisal for selected studies was done by 3 different person, using CEBM Critical Appraisals Tools.
Results
Six studies were selected to be relevant after elaborate search, which was then critically apprasied and found to be valid. Results from all those 6 studies found that weekly vs. triweekly chemoradiation regimen leads to similar survival outcome in nasopharyngeal cancer patients. Overall Survival (OS) rates from those 6 studies showed comparable result among both regimens (3-Year OS, 91% vs 90.8%; 5-year OS, 89% vs. 91%, 85.6% vs 90%, 78.9% vs 85.2%) and, all OS rate outcomes didn’t reach significant difference for all 6 studies.
Conclusions
Weekly and triweekly chemoradiation regimens for nasopharyngeal cancer were shown to be similar in terms of overall survival. The choice of weekly or triweekly chemoradiation for nasopharyngeal cancer patient should tailored according to institutional condition and capability.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract